

CLAIMS

We claim:

1. A MMP expression inhibitor comprising, as an active ingredient, menatetrenone or a pharmacologically acceptable salt thereof, or a hydrate thereof.
5
2. The MMP expression inhibitor according to Claim 1 wherein the MMP is selected from the group consisting of MMP-1, MMP-3, MMP-7 or MMP-14.
3. A uPA expression inhibitor comprising, as an active ingredient, menatetrenone, a pharmacologically acceptable salt thereof, or a hydrate thereof.
10
4. An inhibitor of cancer metastasis and invasion comprising, as an active ingredient, menatetrenone or a pharmacologically acceptable salt thereof, or a hydrate thereof.
15
5. The inhibitor of cancer metastasis and invasion according to Claim 4 wherein the cancer is hepatic cancer.
6. An AP-1 activity inhibitor comprising, as an active ingredient, menatetrenone or a pharmacologically acceptable salt thereof, or a hydrate thereof.
20
7. An Ets-1 expression inhibitor comprising, as an active ingredient, menatetrenone or a pharmacologically acceptable salt thereof, or a hydrate thereof.

8. A prognosis improver for cancer therapy comprising, as an active ingredient, menatetrenone or a pharmacologically acceptable salt thereof, or a hydrate thereof.

5 9. A method for preventing cancer cell metastasis comprising administering an effective dose of menatetrenone or a pharmacologically acceptable salt thereof, or a hydrate thereof in order to inhibit expression of MMP.

10. An expression promoter for CDK inhibitor p16, p21 or p27 comprising, 10 as an active ingredient, menatetrenone or a pharmacologically acceptable salt thereof, or a hydrate thereof.